Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8423993 | 0.98 | HTT (0.42) | HTTPTK2MAPTSLC2A1ALDH1A1 | |
| SCHEMBL3320036 | 0.79 | PTK2 (0.38) | HTTPTK2FGFR1 | |
| SCHEMBL20674123 | 0.79 | HTT (0.47) | HTTPTK2MAPTSLC2A1ALDH1A1 | |
| SCHEMBL19661001 | 0.76 | HTT (0.44) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL23889355 | 0.76 | HTT (0.44) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL4838398 | 0.76 | NOS1 (0.37) | HTTPTK2 | |
| SCHEMBL6850410 | 0.74 | HTT (0.47) | HTTPTK2MAPTSLC2A1ALDH1A1 | |
| SCHEMBL22268064 | 0.73 | HTT (0.41) | HTTPTK2MAPTSLC2A1ALDH1A1 | |
| SCHEMBL21958684 | 0.72 | HTT (0.44) | HTTPTK2MAPTSLC2A1ALDH1A1 | |
| SCHEMBL23703901 | 0.72 | PTK2 (0.33) | HTTPTK2ALDH1A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768764-A | Fused ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021254493-A1 | CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |